Gilead Sciences has entered a multi-programme agreement with Second Genome to discover targets and drug candidates for inflammatory bowel disease (IBD) treatment.
Second Genome announced the first patient has been dosed in a Phase 2 clinical trial evaluating SGM-1019 for the treatment of nonalcoholic steatohepatitis (NASH). SGM-1019 is a first-in-class....